UCLA Advanced Lung Disease & Lung Transplantation Symposium 2026
Advancing Care. Transforming Lives.
State-of-the-Art Therapies for Advanced Lung Disease
The 2026 UCLA Advanced Lung Disease and Lung Transplantation Symposium is an in-person conference, organized by UCLA Health and a multi-disciplinary group of speakers. The goal is to provide updated information on state-of-the-art therapies for patients with end-stage lung disease, including medical and interventional approaches, as well as lung transplantation.
10 Expert Sessions
Three focused sessions covering transplant updates, disease management, and multidisciplinary care
15+ Faculty
World-renowned UCLA physicians, surgeons, and advanced practice providers
In-Person Event
Join us live at the Marriott Marina del Rey for a full day of sessions
5.50 CME Credits
AMA PRA Category 1 Credits™ through PeerPoint Medical Education Institute
Who Should Attend?
This conference is targeted at Pulmonologists, critical care physicians, internists, cardiac and thoracic surgeons as well as allied health professionals who care for patients with advanced lung disease or refer patients for lung transplantation.
Learning Objectives
At the conclusion of the program, participants will be able to:
Evaluate current evidence and emerging innovations in lung transplantation, including candidate selection, donor assessment, organ preservation technologies, and post-transplant outcomes.
Apply contemporary diagnostic and therapeutic approaches for the management of advanced lung diseases, including interstitial lung disease, pulmonary arterial hypertension, bronchiectasis, and advanced COPD.
Recognize clinical factors that influence transplant eligibility and timing of referral for patients with progressive or end-stage lung disease.
Assess management strategies for critically ill patients with acute respiratory failure who may be candidates for lung transplantation.
Interpret evolving diagnostic tools and noninvasive monitoring strategies used in the evaluation and longitudinal care of lung transplant candidates and recipients.
Identify the impact of infectious complications, including respiratory and fungal infections, on transplant candidacy, peri-transplant management, and long-term outcomes.
Integrate cardiac, gastrointestinal, and other systemic comorbidities into comprehensive care plans for patients with advanced lung disease and lung transplantation.
Evaluate the clinical presentation, diagnostic evaluation, and management of emerging causes of advanced lung disease, including artificial stone silicosis.
Collaborate effectively with multidisciplinary team members to optimize care before and after lung transplantation.
Incorporate evidence-based practices and recent clinical advances into the management of patients with advanced lung disease and lung transplant recipients.
Saturday, October 10, 2026
A full day of expert presentations, panel discussions, and networking opportunities
Lung Transplant Updates
Overview of Lung Transplantation in 2026
Advances in Lung Preservation and Assessment — Clinical Breakthroughs
Non-Invasive Diagnostics in Lung Transplantation
Lung Transplant Candidacy — What an Evaluation Entails and Common Pitfalls
Panel Discussion
Advanced Lung Disease Management
Fibrotic Lung Disease — Updates on Diagnostic and Treatment Options
Updates in Pulmonary Arterial Hypertension
Artificial Stone Silicosis: From Emerging Epidemic to Advanced Lung Disease
Panel Discussion
Advanced Lung Disease & Lung Transplantation — A Multidisciplinary Approach
GI Comorbidities and Complications in Advanced Lung Disease and Post Lung Transplant
Fungal Infections and Novel Anti-Fungal Agents
Heart-Lung Transplantation — Evolution and Current Utilization
Advanced Practice Providers — A Pillar of Advanced Lung Disease and Lung Transplant Care
Panel Discussion
World-Class UCLA Physicians
Learn from the leading experts in lung transplantation and advanced pulmonary medicine
Course Co-Directors
Faculty
Secure Your Spot Today
Join us live in person at the Marriott, Marina del Rey. Choose the registration tier that fits your credentials.
Fellows / Residents
- Full-day access
- Live in-person attendance
- 5.50 CME Credits
- Panel discussions
- Networking opportunities
Allied Health Professional
RN, NP, PA-C
- Full-day access
- Live in-person attendance
- 5.50 CME Credits
- Panel discussions
- Networking opportunities
Physician
MD / DO
- Full-day access
- Live in-person attendance
- 5.50 CME Credits
- Panel discussions
- Networking opportunities
Review our .
Venue & Logistics
Marriott, Marina del Rey
4100 Admiralty Way
Marina Del Rey, CA 90292
Questions?
Contact Nexus CME SoCal for registration and event inquiries.
Accreditation & Disclosures
Accreditation and Designation Statements and Disclosure Report
UCLA Advanced Lung Disease & Lung Transplantation Symposium
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and NexusCME SoCal. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.
PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Live activity dates: October 10, 2026
Financial Disclosures
The following planners, presenters, reviewers, editors, or staff have relevant financial relationships to disclose:
“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”
| Full Legal Name | Commercial Interest | Role | Level of participation in the activity |
|---|---|---|---|
| Richard Channick | Merck, Gossamer, Liquida | Consultant | Speaker |
| Penumbra | Advisor | ||
| Pulmovant | Research Funding | ||
| Rajan Saggar | Merck, United Therapeutics, Liquida, Insmed, Pulmovant | Consultant | Speaker |
| S. Samuel Weigt | Sanofi, CareDx, Boehringer Ingelheim, Liquida, United Therapeutics | Consultant | Speaker |
| CareDx, Zambon | Research Funding |
These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and NexusCME SoCal.
All other planners, presenters, reviewers, editors, or staff report no relationships to disclose:
“I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
This activity may include discussion of investigational or off-label uses of products or devices. PeerPoint Medical Education Institute does not endorse or promote the use of any product or device outside of its approved indications.
Disclosure Statement
The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence.
In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous.
The policy further states that all potential conflicts of interest of the NexusCME SoCal's staff and partners be fully disclosed to the program's participants. In addition, ACCME policy mandates that the provider (PeerPoint) adequately manages all identified potential conflicts of interest prior to the program.
Artificial Intelligence (AI) Disclaimer Statement
Consistent with guidance from the Accreditation Council for Continuing Medical Education (ACCME), any individuals in control of content must disclose if artificial intelligence (AI) was used in the development of this educational activity. Such disclosure should include the name of the AI tool(s) utilized and the extent of its role in content creation.
PeerPoint reviews all educational materials to ensure they are evidence-based, balanced, and compliant with ACCME Standards for Integrity and Independence, including the identification and mitigation of any potential biases.
AI technologies may be used to support content development; however, they are not a substitute for clinical expertise. Learners are encouraged to apply independent clinical judgment and critically assess the information presented when making decisions related to patient care.